HC Wainwright & Co. Reiterates Buy on Sana Biotechnology, Maintains $12 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Emily Bodnar reiterated a Buy rating on Sana Biotechnology (NASDAQ:SANA) and maintained a $12 price target.
March 01, 2024 | 11:58 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Sana Biotechnology's stock rating was reiterated as Buy by HC Wainwright & Co. with a maintained price target of $12.
The reiteration of a Buy rating and maintenance of a $12 price target by a reputable analyst firm like HC Wainwright & Co. is likely to instill confidence among investors and could positively influence Sana Biotechnology's stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100